Drugs / SB2
last change Sep 2015 re-read 2 minutes ago

SB2

Developed for
rheumatoid arthritis
Investigated by
Samsung Bioepis Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01936181 Aug 2013 → Sep 2014 rheumatoid arthritis Samsung Bioepis Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SB2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01936181
Route Intravenous “via intravenous infusion” NCT01936181